Navigation Links
Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

New data From 741-patient Trial Show Those Treated with Lumiracoxib Experienced Significantly Smaller Impact on Blood Pressure Compared to Ibuprofen

EAST HANOVER, N.J., June 15, 2007 /PRNewswire/ -- Patients with osteoarthritis who also have controlled hypertension experienced a slight decrease in average daily blood pressure when treated with the investigational selective COX-2 inhibitor lumiracoxib compared to a slight increase in those taking ibuprofen, a commonly-used non-steroidal anti-inflammatory drug (NSAID).

These new results, presented today at the Annual European Congress of Rheumatology (EULAR) in Barcelona, are important because around 40% of patients with osteoarthritis also have high blood pressure (or hypertension).

While this study did not assess long-term cardiovascular outcomes, independent research shows that even small elevations in blood pressure can contribute to an increased risk of cardiovascular events. Osteoarthritis is the most common form of arthritis affecting 21 million Americans.

"NSAIDs, including some COX-2s, have been associated with raised blood pressure, and this effect may be in part responsible for the increased risk of cardiovascular disease associated with this class of medications," said Tom MacDonald, Ph.D., Professor of Clinical Pharmacology at the Hypertension Research Centre at Ninewells Hospital & Medical School in Dundee, Scotland. "These data indicate that lumiracoxib may have less impact on blood pressure than the most commonly used NSAID ibuprofen."

In the US, lumiracoxib 100 mg once-daily is under review by the Food and Drug Administration (FDA) for relief of the signs and symptoms of osteoarthritis.

"Evidence from the large-scale TARGET study has shown that lumiracoxib is associated with significantly smaller increases in blood pressure than commonly used NSAIDs," said James Shannon, MD, Global Head of Development at Nov
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:6/1/2015)... YORK , June 1, 2015   ... of Open, Transparent and Connected financial marketplaces for ... Incorporated, a San Diego -based ... traded on OTCQB®, America,s only public venture market ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ...
(Date:6/1/2015)... , June 1, 2015 /CNW Telbec/ -  Ergoresearch Ltd ... and known under the « Équilibre, orthèses et ... Ended on March 31, 2015. All dollar amounts in the ... for the third quarter of fiscal year 2015 ended this ... to revenues of $ 3,823,151 for the quarter ended March ...
(Date:6/1/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a ... therapies in new orphan drug indications, announced that it ... live webcast today, June 1, 2015, at 5:30 p.m. ... data from its Phase I/II study of VAL-083 ...
Breaking Medicine Technology:OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 4DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 2DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 3DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 4
... Novartis Pharmaceuticals Corporation ("Novartis") announced today that ... Drugs Advisory Committee (ODAC) recommended approval of Afinitor® ... advanced neuroendocrine tumors (NET) of pancreatic origin. ... data from the everolimus RADIANT (RAD001 In Advanced ...
... 12, 2011 MSA (NYSE: MSA ), the ... that protect people,s health and safety, announced today that it ... via the Internet on Thursday, April 28, 2011 at 10:00 ... Investors and interested parties will have the opportunity ...
Cached Medicine Technology:Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10MSA Schedules First Quarter Earnings Webcast 2
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into the NAPW VIP Professional Woman of ... distinction for leadership in academics. With more than 700,000 ... the nation’s leading networking organization exclusively for professional women. ... distinction,” said NAPW President Star Jones. “She is a ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Selma Tansey as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... organization exclusively for professional women, boasting more than 700,000 ... pleased to present Selma with this important honor," said ...
(Date:6/1/2015)... June 01, 2015 Ticket Down announces that ... NBA Western Conference Finals and now will face the Cleveland ... be held at the Oracle Arena in Oakland and the ... 2014-15 National Basketball Association season, the Golden State Warriors were ... a team that learned from their playoff failures from the ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 The Delta ... health programs and organizations in Michigan, Ohio and Indiana ... deadline of Sept. 30, 2015 has been set. , ... in grants to organizations that specifically focus on children’s ... primarily address oral health in adults. Each grant request ...
(Date:6/1/2015)... The Muscular Dystrophy Association is offering an ... the sold out 2015 Bank of America Chicago ... by signing up through the organization's nationwide endurance ... , This national endurance program includes world-class training ... a supportive community of teammates, volunteers, coaches and ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Marcia Ditmyer, Vice President of Academy for Academic Leadership, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3Health News:Brighter Futures Community Grants Program Seeks to Help Fund Local Oral Health Programs 2Health News:Sold Out 2015 Bank of America Chicago Marathon and Marine Corps Marathon Entries Still Available through MDA Team Momentum 2
... study of its kind, scientists from Toronto,s Centre for Addiction and ... a higher risk of developing schizophrenia. This finding was based on ... to a group that did not use drugs, but also to ... published online on Nov. 8, 2011, at AJP in ...
... University of Colorado Denver announced today that it will ... by the Bill & Melinda Gates Foundation that enables ... health and development challenges. Assistant Professor Zhiyong (Jason) ... Applied Science will pursue an innovative global health research ...
... (November 7, 2011) AMRI (NASDAQ: AMRI) announced today ... Eli Lilly and Company, it anticipates hiring more than ... to support Lilly,s drug discovery programs. The chemists will ... they will support the medicinal chemistry department. This ...
... -- ,Neuromuscular warm-ups may reduce knee injuries among female ... neuromuscular warm-up, an athlete begins with easy cardiovascular exercise ... in the sport. The study included 90 ... from public schools in Chicago. Half the coaches were ...
... have been going electronic, and patients, caregivers, and ... digital world of health information. Now three institutions ... populationpeople with disabilitiescan best access this information. ... Inglis Foundation, also based in Philadelphia, are partnering ...
... Hopkins Center for Injury Research and Policy finds fire ... comprehensive and coordinated approach to fire prevention. The study, ... fire service, highlights the diversity of prevention initiatives underway ... a sense of community are keys to success for ...
Cached Medicine News:Health News:CAMH study suggests increased risk of schizophrenia in heavy methamphetamine users 2Health News:Specialized Warm-Up May Reduce Girls' Knee Injuries 2Health News:Grant will help bridge digital divide for people with disabilities 2Health News:Grant will help bridge digital divide for people with disabilities 3Health News:Delaware Fire Service offers important lessons for fire prevention programs nationwide 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: